Danish healthcare company Novo Nordisk A/S (NVO)reported Wednesday that its fiscal 2024 net profit climbed 21 percent to 100.9 ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Geographically, Novo Nordisk posted a 30% sales increase in North America, benefiting from the U.S. market’s strong demand ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen ...

A solid economy and still-too-high inflation argue for holding interest rates steady until more progress is made in slowing price growth, Federal Reserve Vice Chair Philip Jefferson said on Tuesday ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.

You have until March 10, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you are an investor who purchased or otherwise acquired Novo securities during the Class Period. A ...